Toxicology studies in rats and dogs administered AIT-102
Ended Awarded Last action
- Contract number
- 75N91024F00003
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $568,068
Award facts
- Contract value 30% obligated
-
- $568,068.00 Current, with exercised options
- $1,886,133.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $568,068 |
About this award
The National Cancer Institute awarded a $1.89 million cost-plus-fixed-fee delivery order to IIT Research Institute (IITRI) on September 16, 2024, for toxicology studies in rats and dogs involving the experimental compound AIT-102. The work will be performed in Chicago, Illinois, with a completion date of June 30, 2026. This delivery order was issued under one of IITRI's existing indefinite delivery/indefinite quantity (IDIQ) contract vehicles with NCI—specifically the $149.995 million PREVENT Cancer Preclinical Drug Development Program, which extends through January 2029 and supports preclinical efficacy evaluation, analytical testing, process development, and toxicological testing of cancer preventive agents. The award used no set-aside designation and was made through full and open competition.
IITRI, a nonprofit contract research organization and subsidiary of Illinois Institute of Technology, specializes in preclinical drug development services for the National Institutes of Health and other federal agencies. As a recognized leader in good laboratory practice (GLP) and non-GLP toxicology studies, the organization routinely conducts safety evaluations and dose range-finding studies in rodent and canine models to support investigational new drug applications across therapeutic areas including oncology, neurological disorders, and infectious diseases. This contract award reinforces IITRI's established position as a preferred federal contractor for providing sophisticated preclinical toxicology research supporting NCI's drug development mission.
Quick answers
Who was awarded contract 75N91024F00003?
75N91024F00003 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 16, 2024.
How much is contract 75N91024F00003 worth?
The government has obligated $568,068 on 75N91024F00003. Its potential value, with all options, is $1,886,133.
Is contract 75N91024F00003 an order under another contract?
Yes. 75N91024F00003 is a delivery order under 75N91022D00016, an indefinite delivery contract.
Was contract 75N91024F00003 competed?
The extent of competition for 75N91024F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award